Related Experiment Video
Updated: Jul 14, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
Ambulatory blood pressure monitoring and progression in patients with IgA nephropathy
1Nephrological Centre and Second Department of Medicine, University Medical School of Pécs, Hungary.
Insights
Hypertension in IgA nephropathy patients often lacks normal blood pressure dipping patterns and includes white-coat hypertension. These factors accelerate kidney disease progression, highlighting the need for careful monitoring and treatment.
Area of Science:
- Nephrology
- Cardiology
- Hypertension Research
Background:
- Hypertension is a known indicator of poor prognosis in IgA nephropathy.
- Understanding blood pressure patterns is crucial for managing IgA nephropathy progression.
Purpose of the Study:
- To investigate white-coat hypertension prevalence in IgA nephropathy.
- To assess diurnal blood pressure rhythms and antihypertensive treatment effectiveness.
- To determine the impact of these factors on IgA nephropathy progression.
Main Methods:
- 126 IgA nephropathy patients underwent 24-hour ambulatory blood pressure monitoring (ABPM).
- Patients included normotensives and those treated with ACE inhibitors (ACEI) and/or calcium-channel blockers (CCB).
- Serum creatinine levels were monitored over a follow-up period of approximately 36 months.
Main Results:
- Most hypertensive IgA nephropathy patients lacked normal diurnal blood pressure variation ('dipping').
- White-coat hypertension was identified in both normotensive and treated hypertensive groups.
- Hypertensive patients showed increased serum creatinine over time, unlike normotensives. Non-dippers and white-coat hypertensives showed accelerated kidney function decline.
Conclusions:
- Absence of circadian blood pressure rhythm and presence of white-coat hypertension are linked to IgA nephropathy progression.
- ACEI and CCB therapies demonstrated greater efficacy on daytime than nighttime hypertension.
- These findings underscore the importance of ABPM in managing IgA nephropathy.
Background:
Hypertension is a recognized marker of poor prognosis in IgA nephropathy.
Methods:
The present study investigated the prevalence of white-coat hypertension, the diurnal rhythm of blood pressure (BP), the effectiveness of antihypertensive drug therapy, and the effect of the above on the progression of the kidney disease in IgA nephropathy. One hundred twenty-six IgA nephropathy patients were selected consecutively for 24-h ambulatory blood pressure monitoring (ABPM). Fifty-five patients were normotensive and 71 were treated hypertensives. Their antihypertensive drugs were angiotensin-converting enzyme inhibitors (ACEI) alone or in combination with calcium-channel blockers (CCB).
Results:
The mean night-time BP of normotensives (108+/-9/67+/-6 mmHg) was significantly lower than their day-time BP (125+/-8/82+/-7 mmHg, P<0.05). There was no significant difference between the mean day-time and night-time BP in hypertensive patients (125+/-9/82+/-7 mmHg vs 128+/-10/85+/-9 mmHg). The circadian variation of BP was preserved ('dippers') in 82% of the normotensive and 7% of the hypertensive patients (P<0.001). There were 10 'white-coat hypertensives' among the patients classified as normotensives with ABPM (mean office blood pressure 149+/-7/96+/-8 mmHg, 24-h blood pressure 127+/-6/83+/-5 mmHg, P<0.05) and 14 among treated hypertensives (mean office BP 152+/-8/98+/-6 mmHg, 24-h BP 130+/-4/85+/-8 mmHg, P<0.05). There was no difference in mean day-time BP among normotensive and treated hypertensive patients (125+/-8/81+/-5 mmHg vs 128+/-10/85+/-9 mmHg). Hypertensives had significantly higher night-time BP (125+/-9/85+/-9 mmHg) than normotensives (108+/-9/67+/-6 mmHg, P<0.001). There was no difference in serum creatinine levels among the different groups at the time of the ABPM. However, thirty-six+/-4.1 months after the ABPM, hypertensive patients (n=52) had higher serum creatinine levels (124+/-32 micromol/l) than at the time of the ABPM (101+/-28 micromol/l). The serum creatinine of normotensive patients (n=43) did not change during the follow-up period. 'Non-dipper' normotensives (n=10) had significantly higher serum creatinine levels at the end of the follow-up period than at its beginning (106+/-17 micromol/l vs 89+/-18 micromol/l, P<0.05). There was no increase in serum creatinine of 'dipper' normotensives. The mean serum creatinine of 'white-coat hypertensives' was significantly higher at the end of the study period than at its beginning.
Conclusions:
There is no diurnal blood pressure variation in most of the hypertensive IgA nephropathy patients. ACEI and CCB treatment have better effect on day-time than night-time hypertension. The lack of the circadian rhythm and 'white-coat hypertension' seems to accelerate the progression of IgA nephropathy.
Related Concept Videos
Hypertension III: Clinical Manifestations and Diagnostic Studies
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Nephrotic Syndrome III : Nursing Management
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease IV: Nursing Management
Diabetic Nephropathy

